In summary, SCs are increased in pancreatic β-cells and key insulin-regulated metabolic organs with aging, obesity, and diabetes and contribute to inflammation and associated insulin resistance, hyperglycemia, and dyslipidemia, representing an opportunity for therapeutic development for these disorders. The gene discussed is INS; the disease is Hyperglycemia.